Faget Quoted on FDA’s Decision to Stop Reviewing COVID-19 Lab Tests
07 October 2020
BioCentury
Of Counsel Kyle Faget was quoted in a BioCentury article, “FDA to stop reviewing COVID-19 lab tests, raising concerns in Congress,” about the FDA’s announcement that it will no longer review emergency use authorization requests for laboratory developed tests to diagnose COVID-19.
The article cites an Aug. 24 blog post by Faget, who wrote that bringing an LDT to market without securing FDA premarket approval or clearance of, or an emergency use authorization (EUA), comes at a steep cost to clinical laboratories. “Public Health and Emergency Preparedness Act (PREP Act) protection is not available to clinical laboratories opting to use LDTs without FDA premarket review or authorization,” she wrote.
People
Related News
23 April 2025
In the News
Carrie Hoffman Comments on Labor & Employment Issues in the Airline Industry
Foley & Lardner LLP partner Carrie Hoffman shared insight on unique labor and employment issues facing the airline industry in the Law360 article, "4 Wage Issues Facing Airline Crews To Watch."
18 April 2025
In the News
Kyle Hayes Joined NPM Interconnections Podcast to Discuss Green Hydrogen Industry
Foley & Lardner LLP partner Kyle Hayes joined the New Project Media Interconnections podcast to share insights on the state of the green hydrogen industry in the United States.
17 April 2025
In the News
Donald Schroeder Shares Insight on Legislative Push for Gig Driver Unionization
Foley & Lardner LLP partner Donald Schroeder commented on the legislative push for gig driver unionization in the Law360 article, "Minn. Gig Driver Union Bills Raise Employee Status Concerns."